IBSA at the 24th edition of the ESSM09 February 2023
IBSA has always been involved in and committed to the dissemination and research of therapeutic solutions for sexual conditions affecting both males and females and having significant effects on their daily lives, as well as on their personal and social sphere.
One of the first international appointments for IBSA in the field of urogynaecology in 2023 is its participation in the Congress of the European Society for Sexual Medicine (ESSM), to be held in Rotterdam, the Netherlands, from 16 to 18 February. The 24th edition of the ESSM is an opportunity to meet the world’s leading experts in the field of sexual medicine. The congress – which this year will finally be held in presence, after two years of pandemic – will offer the opportunity to learn about the clinical advances and the scientific updates in the field of sexual health, through a rich programme of conferences, debates, round tables and workshops.
THE SYMPOSIUM “OPTIMIZING THE MEDICAL MANAGEMENT OF ERECTILE DYSFUNCTION”
IBSA will support a lecture as part of the symposium “Optimizing the medical management of ED”, which will be held on Friday, February 17, at 2:00 pm. Dr. Andrea Sansone – the first speaker of the event – will introduce the pharmacological treatment of erectile dysfunction, together with clinical practice advice. The programme also includes detailed analyses on issues related to the use of nutraceuticals to optimise the treatment of this condition, in addition to the psychological aspects and couple dynamics. During the congress the debates will be highly interactive, to stimulate discussions and insights and to improve the management of patients with erectile dysfunction.
THE ADVANTAGES OF IBSA TREATMENTS
For IBSA, innovation is a daily challenge, as well as the focal point of all its activities, and it stems from a brilliant intuition: transforming therapeutic solutions with already known properties into simpler and more advanced healthcare tools. The goal is, indeed, to develop treatment systems that are more functional to the real needs of people, in order to improve the quality of their life. For this purpose, IBSA has patented the FilmTec technology in orodispersible film. This technology is also being applied to the treatment of erectile dysfunction, offering a new immediate-release, oral dosage form whose characteristics may improve treatment adherence among people with needs that are not met by capsules and tablets.